Core Insights - Suzhou Yimufeng Biotechnology Co., Ltd. has secured B+ round financing from investors including China Taiping, Boru Capital, Dongwu Venture Capital - Dongwu Securities, and Yueke Financial [1] Company Overview - Yimufeng addresses the treatment challenges of solid tumors and clinical benefits by proposing a novel clinical strategy of transforming "solid tumors into hematological tumors" [1] - The company has developed the Peri Cruiser technology platform, along with SNR and T-Booster technology platforms, aimed at enhancing the safety of CAR-T products, combating tumor heterogeneity, and improving the amplification and infiltration capabilities against tumors [1]